Fluorescent angiography used as a tool to guide angiosome-directed endovascular therapy for diabetic foot ulcers

Marshall Dworak, BS, Elizabeth A. Andraska, MD,a S. Michael Gharacholou, MD,a Melissa Myers, MD,b and Scott C. Chapman, MD,a From the Department of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh; the Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville; and the Department of Critical Care Medicine, Mayo Clinic Health System, La Crosse.

ABSTRACT
Angiosome-directed endovascular therapy for the treatment of chronic limb-threatening ischemia (CLTI) remains controversial owing to the overlap of wound angiosomes. Angiographic grading of success has limitations and transileional pressure assessments are seldom performed in the infrapopliteal vessels. Objective criteria to determine revascularization success in tibiopopliteal vessels have not been well described. Quantifying perfusion to a wound bed after establishing direct or indirect (via collateral) flow after revascularization is an important component for treating CLTI patients yet is seldom performed. We report the use of fluorescent angiography to quantitatively examine perfusion of a diabetic foot ulcer before and after angiosome-directed endovascular therapy. (J Vasc Surg Cases and Innovative Techniques 2021;7:159-63.)

Keywords: Angiosome-directed endovascular therapy; Fluorescent angiography

Chronic limb-threatening ischemia (CLTI) represents the most advanced stage of peripheral vascular disease. It is associated with high rates of amputation and death at 1 year (30% and 25%, respectively).1 Angiosome-directed endovascular therapy uses a concept that wound healing is optimized with direct revascularization of an artery supplying a target angiosome. However, angiosome-directed endovascular therapy for diabetic foot ulcer healing remains controversial. Opponents claim that indirect revascularization via collaterals has similar healing rates, although the amount of collateralization required remains subjective and ill-defined.2 Diabetic patients often lack adequate collaterals owing to progressive diabetic microangiopathy and multivessel involvement. We report the use of fluorescent angiography (FA) to quantitatively examine perfusion of a diabetic foot ulcer before and after angiosome-directed endovascular therapy using a SPY (Stryker Corp., Kalamazoo, Mich) fluorescence imaging platform. The patient consented to the publication of case details and images.

CASE REPORT
A 52-year-old man presented to the emergency room with a few days’ history of flu-like symptoms, hyperglycemia, and a painful, swollen left foot. The patient had a significant past medical history of uncontrolled type I diabetes (hemoglobin A1c of 10.8%), peripheral neuropathy, and tobacco use. On examination, the patient had no fever, normal vitals, and a body mass index of 22. The pulses on the contralateral foot were palpable and nonpalpable on the left foot with biphasic anterior tibial (AT) signal and no posterior tibial (PT) signal. The left medial foot had a malodorous wound with purulent drainage (Fig 1, A) (Wiff score of 232). Laboratories were significant for a white blood count of 15 × 1000/μL and a glucose level of 466. A preoperative foot radiograph demonstrated gas within the soft tissue and no obvious osteomyelitis (Fig 1, B). The patient was taken directly to the operating room for debridement of the infected foot ulcer. The dimensions of the wound were 10 × 4 × 1 cm after sharp debridement of skin, soft tissue, muscle, and tendon (Fig 1, C). The first metatarsal was not involved. The deep tissue culture yielded polymicrobial growth, which included Streptococcus galolyticus and multiple anaerobic bacteria that were not specified. Blood cultures drawn at admission grew Prevotella bivia and Fusobacterium gonadiformans. After successful drainage of the infection and debridement of nonviable tissue, vascular imaging was performed.

Computed tomography angiography demonstrated mild superficial femoral artery disease with one vessel runoff to the left foot via the AT artery. The PT had a short segment occlusion in its distal third with reconstitution at the ankle.
Transcutaneous oxygen pressure measurements were 48 mm Hg at the left calf and 10 mm Hg and 3 mm Hg at the ankle and foot, respectively. A transcutaneous oxygen pressure of less than 40 mm Hg is indicative of tissue hypoxia and inconsistent with wound healing. After medical stabilization of the patient’s organ dysfunction (renal and endocrine) and sepsis, the patient went to the angiography suite for endovascular angiosome-directed revascularization for limb salvage.

SPY FA of the left foot wound was performed initially and showed an ingress rate of 3.3 U/second (baseline) (Fig 2, B). After obtaining contralateral access, weight-based heparin was administered, and a selective left leg runoff was performed. Angiography demonstrated a chronic total occlusion in the mid to distal PT that filled distally by small, diseased collaterals off the AT (Fig 2, A). Successful recanalization of the PT was achieved using orbital atherectomy (a Diamondback 360 peripheral orbital atherectomy system, CSI, St. Paul, Minn) and gentle balloon angioplasty (Fig 3, A). SPY FA was then repeated. Quantitative analysis showed an increase from 3.3 U/second to 29.5 U/second, a total increase of 805% (Fig 3, B). Previous unseen fluorescence in the medial plantar (Fig 4, A) before the intervention was now easily visualized (Fig 4, B). Based on the intraprocedural SPY FA results, the procedure was terminated, and limb salvage was anticipated. The patient tolerated the procedure well and was discharged home. A successful, outpatient split-thickness skin graft was performed, and the wound was nearly healed at 4 to 6 weeks after initial debridement with interval skin grafting.

DISCUSSION

Angiosome theory was first proposed by Taylor and Palmer in 1987, who investigated blood supply to the skin and underlying tissues by ink injection studies, gross dissection, perforator mapping, and radiographic analyses of cadavers and isolated limbs. They defined angiosomes as a three-dimensional unit of skin and deep tissue supplied by source arteries and drained by source veins. Their findings have been classified into six main foot angiosomes. Three of these are fed by the PT, one by the AT, and two by the peroneal artery. Angiosome-directed endovascular therapy aims at recanalizing specific arteries that directly feed the wound or ulcer bed as compared with indirect revascularization, which relies on collateral flow from adjacent angiosomes.

The Global Vascular Guidelines recommend that angiosome-directed revascularization be considered in treating mid/hind foot lesions and lesions with advanced limb threat, because this practice seems to most notably improve wound healing. Critics of angiosome-directed therapy claim foot wounds often have nebulous angiosome assignments, heterogeneous vascular anatomy, and frequently extend over multiple angiosomes. However, for more proximal foot lesions, specific artery/angiosome assignment occurs in 75% to 80% of cases.

Jongsma et al found that direct revascularization showed similar long-term outcomes to patients who underwent indirect revascularization (with patent collaterals). In patients with diabetes, microangiopathy can negatively impact collateral circulation, complicating indirect revascularization. There is compelling evidence that direct revascularization using angiosome-directed endovascular therapy is superior to indirect...
Proponents of this technique have documented improved wound healing rates and amputation-free survival in patients with diabetic foot ulcers. Angiosome-directed therapy should be weighed based on ulcer location, crural arterial anatomy, and degree of collateralization.

Currently, there is no standard for intraoperative measurement of tissue perfusion. Indocyanine green (ICG) is a long-standing contrast agent that has been approved by the US Food and Drug Administration since 1959. It is an inert, water-soluble, nontoxic agent with a short half-life of 3 to 5 minutes, a very low rate of adverse effects, and hepatic clearance; as such, it is a viable option for patients with kidney disease. ICG's brief half-life permits repeat assessments during the same procedure. A standard ICG dose of 3 mL of a 2.5 mg/mL solution is recommended by the manufacturer and followed by our practice for the evaluation of peripheral perfusion.
SPY system contains a near-infrared laser light source and charge-coupled camera that detects local ICG fluorescent tissue perfusion. The SPY system has a versatile imaging head that holds the laser diode ray, charge-coupled camera, and distance sensor. The camera is then positioned based on the range bar shown on the monitor (Fig 5). It can illuminate a maximum field of $18.5 \times 13.5 \text{ cm}^2$, with image sequences at 3.75 to 30.00 frames per second depending on recording time ranging from 30 seconds to 4.5 minutes.\textsuperscript{13,14} From this, values such as ingress, ingress rate (rate at which fluorescence intensity increases on imaging field), peak perfusion (ie, maximum intensity), egress, and egress rate are quantitatively determined while simultaneously displaying qualitative visual results.

SPY using ICG has been adapted by many other surgical disciplines, but has yet to be widely used for limb salvage. Braun et al\textsuperscript{15} showed statistically significant improvements in ingress, ingress rate, curve integral, end intensity, egress, and egress rate after revascularization treatment in patients with CLTI. In the largest prospective study assessing SPY technology in peripheral interventions to date, Colvard et al\textsuperscript{16} showed statistically significant improvements in ingress rate and peak perfusion after revascularization procedures for CLTI. They argue FA may serve as a marker for procedural success especially in diabetic patients with noncompressible ankle-brachial indices (ABI) or unavailable toe pressure (TP) measurements owing to tissue loss or infection.

Limitations in the use of SPY FA include the costs associated with the product, variable insurance reimbursement, unestablished threshold values, limited tissue penetration of 5 mm, and a lack of beneficial effect in amputation rate reduction. FA has not been well-studied in the treatment of CLTI; however, it may prove useful in real-time decision making. SPY FA may have the potential to predict wound healing during angiosome-directed therapy. Further investigation on its role in the management of diabetic foot ulcers and limb salvage is warranted.

Currently, there are no reported surveillance data in the literature supporting normal SPY values or threshold levels required for wound healing or relief of CLTI. The clinical interpretation of SPY values remains undefined given ICG variance among individuals and wound beds.
Settembre et al.17 evaluated the FA, ABI, and TP in 104 limbs before and after endovascular or open revascularization. An ABI could not be obtained in 57% owing to medial calcinosis and TPs in 48.5%, mostly owing to previous tissue loss. FA was technically successful in all limbs, and the SPY values failed to increase in 8.8% who underwent successful revascularization and none who failed revascularization.17

In this case, SPY FA provided intraprocedural information after recanalization of the PT with regard to the microperfusion of the wound bed. Wound ICG uptake was measured and compared with baseline values obtained prior to draping. Given the substantial visual and numerical intensity improvement of ICG, no attempt was made to restore flow to the dorsalis pedis and pedal arch. The marked improvement in SPY FA rate increase suggested limb salvage was probable, and it was reasonable to consider future split thickness skin grafting. The usefulness of SPY FA may be especially beneficial in cases in which in-line flow cannot be established. The added cost of SPY FA may be justified by its accurate assessment of tissue perfusion, ease of intraprocedural use to assist in real-time decision making, and cost reduction associated with avoiding unnecessary or futile limb salvage interventions.

CONCLUSIONS

SPY FA is a useful tool for evaluating perfusion and may guide the adequacy of endovascular interventions particularly in mid to hind foot lesions, and in cases where the affected angiosome has poorly developed collateral circulation. FA using ICG is a practical method of demonstrating perfusion before and after angiosome-directed endovascular therapy. It provides objective data in real time to assess if the intervention improved the microvascular perfusion of a wound which may be especially useful in cases where in-line flow could not be established. Further investigation in the use FA to direct angiosome-directed therapy is needed.

REFERENCES

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the management of peripheral arterial disease (TASC II). Int Angiol 2007;26:82-157.

2. Varela C, Francisco A, de Haro J, Bleda S, Esparza L, March JR. The role of foot collateral vessels on ulcer healing and limb salvage after successful endovascular and surgical distal procedures according to an angiosome model. Vasc Endovasc Surgery 2010;44:654-60.

3. Fife CE, Smart DR, Sheffield PJ, Hopf HW, Hawkins G, Clarke D. Transcutaneous oximetry in clinical practice: consensus statements from an expert panel based on evidence. Undersea Hyperb Med 2009;36:43-53.

4. Taylor GI, Palmer JH. The vascular territories (angiosomes) of the body: experimental study and clinical applications. Br J Plast Surg 1987;40:113-41.

5. Attinger CE, Evans KK, Bulan E, Blume P, Cooper P. Angiosomes of the foot and ankle and clinical implications for limb salvage: reconstruction, incisions, and revascularization. Plast Reconstr Surg 2006;117:261s-93s.

6. Conte MS, Bradbury AW, Kohl P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:1-109.

7. Aarden D, Denecker N, Gallala S, Debing E, Van den Brande P. Wound morphology and topography in the diabetic foot: hurdles in implementing angiosome-guided revascularization. Int J Vasc Med 2014;2014:1-6.

8. Špillarova K, Sorderstrom M, Albäck A, Venermo M. The feasibility of angiosome-targeted endovascular treatment in patients with critical limb ischemia and foot ulcer. Ann Vasc Surg 2016;30:270-6.

9. Jongsma H, Bekken JA, Akkersdijk GP, Hoeks SE, Verhagen HJ, Fioole B. Angiosome-directed revascularization in patients with critical limb ischemia. J Vasc Surg 2017;65:1208-19.

10. Soderstrom M, Alback A, Biancar F, Lappalainen K, Lepantalo M, Venermo M. Angiosome-targeted infrapopliteal endovascularization for treatment of diabetic foot ulcers. J Vasc Surg 2013;57:427-35.

11. Alexandrescu V, Vincent G, Azdak K, Hubermont G, Ledent G, Ngongang C, et al. A reliable approach to diabetic neuroischemic foot wounds: below-the-knee angiosome oriented angioplasty. J Endovasc Ther 2011;18:376-87.

12. Cherrick GR, Stein SW, Leevy CM, Davidson CS. Indocyanine green angiography: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest 1960;39:592-600.

13. Gurtner GC, Jones GE, Neligan PC, Newman MI, Phillips BT, Sacks JM, et al. Intraoperative laser angiography using the SPY system: review of the literature and recommendations for use. Ann Surg Innov Res 2013;7:1.

14. Joh JH, Park HC, Han SA, Ahn HJ. Intraoperative indocyanine green angiography for the objective measurement of blood flow. Ann Surg Treat Res 2016;90:279-86.

15. Braun JD, Trinidad-Hernandez M, Perry D, Armstrong DG, Mills JL. Early quantitative evaluation of indocyanine green angiography in patients with critical limb ischemia. J Vasc Surg 2015;55:1218-23.

16. Colvard B, Itoga NK, Hitchner E, Sun Q, Long B, Lee G, et al. SPY technology as an adjunctive measure for lower extremity perfusion. J Vasc Surg 2016;64:195-201.

17. Settembre N, Kauhanen P, Alback A, Spillerova K, Venermo M. Quality control of the foot revascularization using indocyanine green fluorescence imaging. World J Surg 2017;41:1919-26.

Submitted Jul 30, 2020; accepted Oct 19, 2020.